EssilorLuxottica Reports Six-Month Interim Results for Stellest 2.0 Lens Matching First-Generation One-Year Outcomes

EssilorLuxottica reported six-month interim findings from an ongoing randomized, double-masked clinical trial in China for its Essilor Stellest 2.0 lens design. The study showed treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation compared to single-vision lenses. These results are comparable to those previously reported after 12 months with first-generation Stellest lenses, suggesting a potentially accelerated response using H.A.L.T. MAX technology. Principal investigator Professor Yang Xiao noted the treatment response appeared approximately twice as fast. Over 90% of children wore the spectacles more than 12 hours daily, and 98% adapted within one week. The trial remains ongoing, with one-year analysis serving as the primary efficacy endpoint.